Genmab AS (GMAB : NASDAQ)
Common Stock
$44.67
USD
-0.02 (-0.03%)
Last updated: 2026-10-27
Follow GMAB
GMAB
Genmab AS
WealthAwesomePerformance
1 Day
-0.03%
1 Week
+14.33%
1 Month
+26.47%
YTD
+40.38%
Key Statistics
Market Cap
$27.47B
52W High
$45.45
52W Low
$23.62
P/E Ratio
35.17
50 Day MA
$35.71
200 Day MA
$30.17
Beta
0.65
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/27/2026 | $44.41 | $44.99 | $43.98 | $44.67 | $44.67 | 4,928,899 |
| 10/26/2026 | $44.79 | $45.45 | $44.08 | $44.69 | $44.69 | 7,366,926 |
| 10/23/2026 | $39.84 | $44.34 | $39.63 | $43.79 | $43.79 | 12,999,000 |
| 10/22/2026 | $39.67 | $40.16 | $39.50 | $40.00 | $40.00 | 4,604,382 |
| 10/21/2026 | $39.08 | $39.66 | $39.05 | $39.57 | $39.57 | 2,972,767 |
| 10/20/2026 | $38.60 | $39.41 | $38.41 | $39.07 | $39.07 | 3,777,521 |
| 10/19/2026 | $37.89 | $39.00 | $37.76 | $38.50 | $38.50 | 4,775,871 |
| 10/16/2026 | $38.15 | $38.20 | $36.74 | $37.00 | $37.00 | 2,684,700 |
| 10/15/2026 | $37.20 | $38.33 | $37.04 | $37.82 | $37.82 | 4,083,528 |
| 10/14/2026 | $36.38 | $37.24 | $36.13 | $36.89 | $36.89 | 2,687,385 |
Analyst Price Targets
Based on 12 analysts covering GMAB · as of Oct 27, 2026
Wall Street analysts forecast GMAB stock price to rise 8.1% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
US$48.27
+8.1% Upside
Previously US$45.95 on Oct 26, 2026
Current Price
US$44.67
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GMAB's historical volatility
30-Day Vol
46.2%
Annualized
90-Day Vol
36.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$53.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$47.41 | US$40.43 – US$55.60 |
| 60 trading days | US$50.32 | US$40.17 – US$63.03 |
| 90 trading days | US$53.40 | US$40.53 – US$70.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Financials
- Revenue (TTM)
- $4.13B
- EBITDA
- $1.38B
- Profit Margin
- 19.08%
- ROE (TTM)
- 14.00%
- EPS (Diluted)
- 1.27
- Book Value
- 9.98
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GMAB.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NUWE | Nuwellis Inc | $5.41 | +1590.63% |
| ENLV | Enlivex Therapeutics Ltd | $2.70 | +1460.69% |
| QETAR | Quetta Acquisition Corporation Right | $0.68 | +70.00% |
| BRAI | Braiin Limited Common Stock | $3.31 | +56.13% |
| IRHOR | Iron Horse Acquisitions Corp. II Rights | $0.14 | +49.83% |
| FSHPR | Flag Ship Acquisition Corp. Right | $0.10 | +47.06% |
| AEYE | AudioEye Inc | $10.14 | +36.66% |
| MBRX | Moleculin Biotech Inc | $9.27 | +30.77% |
GMAB.US news timeline
4 articles covering GMAB.US, most recent first
Latest